Transcriptional modulation unique to vulnerable motor neurons predicts ALS across species and SOD1 mutationsShow others and affiliations
2025 (English)In: Genome Research, ISSN 1088-9051, E-ISSN 1549-5469, Vol. 35, no 9, p. 1975-1991Article in journal (Refereed) Published
Abstract [en]
Amyotrophic lateral sclerosis (ALS) is characterized by the progressive loss of motor neurons (MNs) that innervate skeletal muscles. However, certain MN groups including ocular MNs, are relatively resilient. To reveal key drivers of resilience versus vulnerability in ALS, we investigate the transcriptional dynamics of four distinct MN populations in SOD1G93A ALS mice using LCM-seq and single molecule fluorescent in situ hybridization. We find that resilient ocular MNs regulate few genes in response to disease. Instead, they exhibit high baseline gene expression of neuroprotective factors including En1, Pvalb, Cd63 and Gal, some of which vulnerable MNs upregulate during disease. Vulnerable motor neuron groups upregulate both detrimental and regenerative responses to ALS and share pathway activation, indicating that breakdown occurs through similar mechanisms across vulnerable neurons, albeit with distinct timing. Meta-analysis across four rodent mutant SOD1 MN transcriptome datasets identify a shared vulnerability code of 39 genes including Atf4, Nupr1, Ddit3, and Penk, involved in apoptosis as well as proregenerative and anti-apoptotic signature consisting of Atf3, Vgf, Ina, Sprr1a, Fgf21, Gap43, Adcyap1, and Mt1 Machine learning using genes upregulated in SOD1G93A spinal MN predicts disease in human stem cell-derived SOD1E100G MNs, and shows that dysregulation of VGF, INA, and PENK are strong disease-predictors across species and SOD1 mutations. Our study reveals MN population-specific gene expression and temporal disease-induced regulation that together provide a basis to explain ALS selective vulnerability and resilience and that can be used to predict disease.
Place, publisher, year, edition, pages
Cold Spring Harbor Laboratory Press (CSHL), 2025. Vol. 35, no 9, p. 1975-1991
National Category
Neurosciences
Identifiers
URN: urn:nbn:se:oru:diva-122803DOI: 10.1101/gr.279501.124ISI: 001563623100001PubMedID: 40675818Scopus ID: 2-s2.0-105014762496OAI: oai:DiVA.org:oru-122803DiVA, id: diva2:1990220
Funder
Ulla-Carin Lindquist Foundation for ALS-ResearchSwedish Research Council, 2016-02112Swedish Research Council, 2020-01049
Note
This work was supported by grants from the Swedish Research Council (2016-02112 and 2020-01049) to E.H.; the European Union Joint Programme for Neurodegenerative Disease (JPND) (529-2014-7500) to E.H.; the Department of Biochemistry and Biophysics, Stockholm University to E.H.; Ahlen's Foundation (ahlen-stiftelsen) to E.H.; the Ulla-Carin Lindquists Foundation for ALS research (Ulla-Carin Lindquists stiftelse foer ALS forskning) to E.H.; and Birgit Backmark's donation to ALS research at Karolinska Institute (Birgit Backmark's Donation till ALS forskning vid Karolinska Institutet) to E.H. I.L. has been financed by a MESR ("French ministry for high education and research") PhD fellowship. Project-related funding for C.S.L. comes from the French National ALS Association ("Association pour la recherche sur la SLA-ARSLA") and additional ALS associations ("Aide a la Recherche des Maladies du Cerveau-ARMC," and "SLA Fondation Recherche-SLAFR"). C.S.L. thanks the staff of the animal housing facility UMS28/CEF (Paris, France) and of the iGenSeq platform for genotyping (ICM, Paris, France, which received funding from the program "Investissements d'avenir" ANR-10-IAIHU-06).
2025-08-192025-08-192026-01-23Bibliographically approved